Choline phospholipid metabolism: A target in cancer cells?

Journal of Cellular Biochemistry

Volumn 90, Issue 3, 2003, Pages 525-533

  Ackerstaff, Ellen ^b   Glunde, Kristine ^b   Bhujwalla, Zaver M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cancer; Choline phospholipid metabolism; Magnetic resonance

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE;

CACHEXIA; CANCER; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CELL SURVIVAL; DEATH; HUMAN; MULTIPLE ORGAN FAILURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SOLID TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHOLINE KINASE; ENDOTHELIAL CELLS; FEMALE; HUMANS; INDOMETHACIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASMS; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE;

EID: 0141954157     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10659     Document Type: Review

References (39)

1. Aboagye EO, Bhujwalla ZM. 1999. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59:80-84.
2. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. 2001. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61:3599-3603.
3. Ackerstaff E, Artemov D, Bhujwalla ZM. 2003. Reduced invasion of human breast cancer cells after anti-inflammatory treatment: "11th Scientific Meeting & Exhibition of the International Society for Magnetic Resonance in Medicine." Toronto, Ont., Canada. abstract # 836.
4. 31P MR spectral alterations in human hepatic tumours. NMR Biomed 11:354-359.
5. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. 1996. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 56:4630-4635.
6. 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med 41:897-903.
7. Bogin L, Papa MZ, Polak-Charcon S, Degani H. 1998. TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim Biophys Acta 1392:217-232.
8. Cai H, Erhardt P, Troppmair J, Diaz-Meco MT, Sithanandam G, Rapp UR, Moscat J, Cooper GM. 1993. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction. Mol Cell Biol 13:7645-7651.
9. Cullis PR, Hope MJ. 1991. Physical properties and functional roles of lipids in membranes. In: Vance DE, Vance J, editors. Biochemistry of lipids, lipoproteins, and membranes. Amsterdam: Elsevier Science Publishers. pp 1-41.
10. 31P MRS of experimental tumours. NMR Biomed 6:345-365.
11. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
12. 31P MR spectroscopy study using a continuous bioreactor system. Magn Reson Med 33:422-426.
13. 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med 48:819-825.
14. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. 1999. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 19:1737-1746.
15. Guthridge CJ, Stampfer MR, Clark MA, Steiner MR. 1994. Phospholipases A2 in ras-transformed and immortalized human mammary epithelial cells. Cancer Lett 86:11-21.
16. Hernandez-Alcoceba R, Fernandez F, Lacal JC. 1999. In vivo antitumor activity of choline kinase inhibitors: A novel target for anticancer drug discovery. Cancer Res 59:3112-3118.
17. Kaiser E, Chiba P, Zaky K. 1990. Phospholipases in biology and medicine. Clin Biochem 23:349-370.
18. Katz-Brull R, Degani H. 1996. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 16:1375-1380.
19. Kiss Z, Crilly KS, Anderson WH. 1993. Carcinogens stimulate phosphorylation of ethanolamine derived from increased hydrolysis of phosphatidylethanolamine in C3H/101/2 fibroblasts. FEBS Lett 336:115-118.
20. Kurhanewicz J, Vigneron DB, Nelson SJ. 2000. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2:166-189.
21. 31P measurements of response to treatment. NMR Biomed 11:314-340.
22. Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. 2002. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging 16:229-237.
23. Lupulescu A. 1996. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54:83-94.
24. Mori N, Natarajan K, Chacko VP, Artemov D, Bhujwalla ZM. 2003. Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol Imaging 2:124-130.
25. Natarajan K, Mori N, Artemov D, Bhujwalla ZM. 2002. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and nm23 expression. Neoplasia 4:409-416.
26. Negendank W. 1992. Studies of human tumors by MRS: A review. NMR Biomed 5:303-324.
27. Noguchi M, Rose DP, Earashi M, Miyazaki I. 1995. The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology 52:265-271.
28. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS. 2000. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161:207-214.
29. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, DiFiore PP, Aaronson SA. 1991. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6:1189-1194.
30. Podo F. 1999. Tumour phospholipid metabolism. NMR Biomed 12:413-439.
31. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. 2002a. Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene 21:4317-4322.
32. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. 2002b. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296:580-583.
33. Ronen SM, Jackson LE, Beloueche M, Leach MO. 2001. Magnetic resonance detects changes in phosphochohne associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 84:691-696.
34. Rozic JG, Chakraborty C, Lala PK. 2001. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness, and angiogenesis. Int J Cancer 93:497-506.
35. 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res 55:5140-5145.
36. Swindle P, McCredie S, Russell P, Himmelreich U, Khadra M, Lean C, Mountford C. 2003. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 228:144-151.
37. Ting YL, Sherr D, Degani H. 1996. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 16:1381-1388.
38. Yamashita S, Yamashita J, Ogawa M. 1994. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69:1166-1170.
39. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Foster DA. 2003. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 302:615-619.